Chat GPT Summarizes MRD Titles at ESMO Berlin 2025

See ESMO MRD titles at Svetlana Nikic's Linked In:

https://www.linkedin.com/posts/svetlananikic_esmo25-mrd-posters-activity-7384117083703246848-CSzX  

Chat GPT 5 reads the titles.

##

ESMO 2025 Trends and Highlights – MRD Landscape (Berlin, October 2025)

Minimal residual disease (MRD) took center stage at ESMO 2025, reflecting a maturing field that’s rapidly integrating liquid biopsy technologies into real-world oncology practice. The abstracts revealed broad tumor coverage—from colorectal and lung to hepatocellular, renal, and breast cancers—showing MRD’s move from niche research to clinical decision-making.

Key trends included a strong emphasis on methylation and fragmentomics as next-generation biomarkers beyond standard ctDNA variant detection. Several tissue-agnostic and “blood-only” assays suggest a drive toward simpler, scalable MRD monitoring. Clinically, MRD-guided adjuvant therapy decisions were validated across colorectal, lung, and urothelial studies, with major multicenter prospective designs like PRECISION and CURATE-UTUC underscoring growing regulatory and payer readiness.

A notable surprise was the emergence of immunotherapy-linked MRD—seen in perioperative NSCLC trials and post-chemoradiation head-and-neck protocols—marking convergence between MRD biology and immuno-oncology. Beyond cancer type, interest is shifting toward patient experience and health economics, with new studies exploring cost-effectiveness and attitudes toward liquid biopsy follow-up.

Overall, ESMO 2025 signaled that MRD is no longer experimental—it’s becoming a clinical, cross-tumor biomarker ecosystem, poised to reshape treatment surveillance and response assessment.